TICKERNERD
Menu
IPSCIPSCHealthcare · Biotechnology

IPSC Stock Forecast: Century Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.12
+2.42% on the day

The 5 Wall Street analysts covering Century Therapeutics, Inc. hold a median 12-month price target of $4.5 — +112.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$374.8M
Ticker Nerd rank
39 / 100
Median analyst target
$4.50
Analysts covering
5
Total return, dividends reinvested
1W
+8.7%
1M
+0.5%
YTD
+113.1%
1Y
+291.9%
From 52W high
−27.9%
From 52W low
+355.9%
$0.47
$2.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IPSC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
89
Accruals
63
Size
58
Quality
58
Issuance
51
Revisions
38
Value
33
Volatility
19
Growth
10

Momentum (89): The shares have been drifting up relative to others.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IPSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26IPSCHigh $8.00Median $4.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $2.00Median $4.50High $8.00

The green dot is the last close — the median target sits +112.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 May 2026MizuhoInitiatesOutperform$8.00
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
17 Nov 2025Leerink PartnersDowngradeMarket Perform—
16 May 2025Chardan CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025GuggenheimReiteratesBuy—
24 Mar 2025Chardan CapitalMaintainsBuy—
21 Mar 2025GuggenheimMaintainsBuy—
20 Mar 2025Piper SandlerMaintainsOverweight—
22 Jan 2025GuggenheimReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024Piper SandlerMaintainsOverweight—
7 Nov 2024Chardan CapitalMaintainsBuy—
6 Nov 2024HC Wainwright & Co.MaintainsBuy—
15 Aug 2024HC Wainwright & Co.MaintainsBuy—
17 June 2024Piper SandlerMaintainsOverweight—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.MaintainsBuy—
12 Apr 2024Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IPSC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IPSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Century Therapeutics, Inc. (IPSC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.7×

Cheaper than 95% of US stocks

Price / sales
3.4×

Cheaper than 37% of US stocks

Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
−3.1×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−9.6%

Higher than 25% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−49.7%

Higher than 21% of US stocks

Return on assets
−23.5%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IPSC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IPSCCentury Therapeutics, Inc.$374.8M
39
GALTGalectin Therapeutics, Inc.$371.1M
77
PALIPalisade Bio, Inc.$366.0M
36
RCKTRocket Pharmaceuticals, Inc.$379.9M
52
LYELLyell Immunopharma, Inc.$380.6M
65
UPBUpstream Bio, Inc.$381.8M
31
ZNTLZentalis Pharmaceuticals, Inc.$362.1M
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IPSC news & analysis

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 12 Aug 2026positive

Century Therapeutics reported second quarter 2026 financial results, including $197.2 million in cash with a runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, with an IND submission on track for the fourth quarter of 2026, and remains on track to advance CNTY-308 into the clinic this year.

Why it matters — For IPSC watchers, the progress of CNTY-813 toward an IND, positive preclinical data, and the planned clinical advancement of CNTY-308 represent key developmental milestones for the company's iPSC-derived cell therapy pipeline.

FAQ

Frequently asked questions about IPSC stock

What is the IPSC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Century Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IPSC stock a buy right now?

Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IPSC?

As at 22 Aug 2026, Century Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).

Will IPSC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +112.3% from the last close, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 39 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IPSC stock forecast for 2030?

No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has IPSC stock performed over the past year?

Century Therapeutics, Inc. returned +291.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Century Therapeutics, Inc. do?

Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment.

What is the latest news on IPSC?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates". Century Therapeutics reported second quarter 2026 financial results, including $197.2 million in cash with a runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, with an IND submission on track for the fourth quarter of 2026, and remains on track to advance CNTY-308 into the clinic this year.

Company

About Century Therapeutics, Inc.

Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision. Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities. In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.

CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com